Johnson & JohnsonvsStandard BioTools

JNJ and LAB stock compared: price, dividend, valuation and results, from SEC filings.

LAB

Standard BioTools Inc.

$0.62

Value $242M

-12.54%
LAB's page

Johnson & Johnson (JNJ) has a market value of $681B and Standard BioTools (LAB) $242M. Over the last year, with dividends, JNJ moved +47.5% and LAB -49.9%. Dividend yield: JNJ 1.87%, LAB none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$681B

    LAB$242M

    JNJ is 2,811 times LAB

  • Revenue, 12 months

    JNJ$99.3B

    LAB$84M

    JNJ is 1,177 times LAB

  • Net income, 12 months

    JNJ$16.1B

    LAB$133M

    JNJ is 121 times LAB

  • Operating margin

    JNJ–

    LAB-97.5%

  • ROIC

    JNJ12.4%

    LAB-13.1%

    25.5 points apart

  • P/E

    JNJ42.3

    LAB–

  • Dividend yield

    JNJ1.9%

    LAB0.0%

    1.9 points apart

  • 5-year return

    JNJ+98.6%

    LAB-87.0%

    185.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+98.6%

LAB-86.9%

10020020222023202420252026
Returns by period
PeriodJNJWith dividendsLABWith dividends
1 year since November 14, 2025+47.5%Price +44.2%-49.9%Price -49.9%
3 years since November 16, 2023+105.0%+27.0% a yearPrice +88.2%-71.8%-34.4% a yearPrice -71.8%
5 years since November 15, 2021+98.6%+14.7% a yearPrice +72.8%-87.0%-33.5% a yearPrice -87.0%
10 years since November 16, 2016+218.6%+12.3% a yearPrice +142.8%-89.7%-20.3% a yearPrice -89.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonLABStandard BioTools

Valuation

JNJLAB
Valuation
Price$282.55$0.62
Market value$681B$242M
Enterprise value (EV)$708B–
P/E42.3–
P/E, 5-year median21.9–
P/B8.40.4
EV/EBIT39.9–
Free cash flow yield3.0%–

Results and growth

JNJLAB
Results and growth
Revenue, 12 months$99.3B$84M
Net income, 12 months$16.1B$133M
Free cash flow, 12 months$20.6B-$66M
Earnings per share, 12 months$6.59$0.34
Revenue growth, year on year6.1%-6.2%
Revenue growth a year, past+2.7%over 5 years-9.2%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJLAB
Margins and returns on capital
Gross margin67.6%52.2%
Operating margin–-97.5%
Net margin16.2%157.6%
ROIC12.4%-13.1%
ROE19.7%26.8%

Balance sheet

JNJLAB
Balance sheet
Cash$17.2B$461M
Total debt$44.7B$27M
Net debt / EBITDA1.1–
Interest cover18.0×–

Dividends and buybacks

JNJLAB
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.7%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or LAB

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Standard BioTools?

By market value, Johnson & Johnson ($681B) is about 2,811.0 times Standard BioTools ($242M), at today's prices.

How did JNJ and LAB stock do over the last 10 years?

Since November 16, 2016, JNJ's price moved +142.8% and LAB's -89.7%. With dividends: JNJ +218.6% (+12.3% a year), LAB -89.7% (-20.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or LAB?

The dividend yield at today's price is 1.87% for Johnson & Johnson and none for Standard BioTools. Over the last twelve months they paid $5.28 and – per share.

Which has the higher profit margins, Johnson & Johnson or Standard BioTools?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 157.6% for Standard BioTools, and the operating margin – and -97.5%. Revenue was $99.3B and $84M.

Which is the better investment, Johnson & Johnson or Standard BioTools?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.